Healthcare Stocks

UK's CMA Says Portman Healthcare-Dentex Healthcare Deal Raises Competition Concerns

  • February 03, 2023 12:57 PM GMT | Reuters
 UK's CMA Says Portman Healthcare-Dentex Healthcare Deal Raises Competition Concerns

Feb 3 (Reuters) - UK's Competition and Markets Authority: * CMA: FOUND PORTMAN HEALTHCARE-DENTEX HEALTHCARE DEAL RAISED COMPETITION CONCERNS WHICH COULD HARM TREATMENT FOR PATIENTS IN SOUTH WEST,

Read More...
Immunocore Reports Third Quarter 2022 Financial Results

Immunocore Reports Third Quarter 2022 Financial Results

  • November 09, 2022 12:34 PM GMT | Reuters

Nov 9 (Reuters) - Immunocore Holdings Plc: * IMMUNOCORE REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE * CASH AND CASH EQUIVALENTS OF $387 MILLION AS OF SEPTEMBER 30, 2022 *

Read More...
Verona Pharma PLC reports results for the quarter ended in September - Earnings Summary

Verona Pharma PLC reports results for the quarter ended in September - Earnings Summary

  • November 09, 2022 08:01 AM GMT | Reuters

* Verona Pharma PLC reported a quarterly adjusted loss of 23 cents​​ per share for the quarter ended in September. The mean expectation of seven analysts for the quarter was for a loss of 16 cents per

Read More...
Verona Pharma PLC <VRNA.O>: Losses of 23  cents announced for third quarter

Verona Pharma PLC <VRNA.O>: Losses of 23  cents announced for third quarter

  • November 09, 2022 08:01 AM GMT | Reuters

9 November 2022 08:01 a.m. ​All figures in US dollars. The loss announced by Verona Pharma PLC in the third quarter were lower than the Refinitiv mean estimate of losses. The company reported losses

Read More...
Sareum Holdings No Longer Sees SDC-1801 Trial To Start Before 2022 End

Sareum Holdings No Longer Sees SDC-1801 Trial To Start Before 2022 End

  • November 08, 2022 05:26 PM GMT | Reuters

Nov 8 (Reuters) - Sareum Holdings PLC: * SAREUM HOLDINGS PLC - UPDATE ON SDC-1801 CTA APPLICATION * SAREUM HOLDINGS - UK MHRA HAS GIVEN NOTICE TO CO THAT IT DID NOT APPROVE CTA TO EVALUATE SAFETY AND

Read More...
Adaptimmune Therapeutics PLC <ADAP.O>: Losses of 24  cents announced for third quarter

Adaptimmune Therapeutics PLC <ADAP.O>: Losses of 24  cents announced for third quarter

  • November 08, 2022 04:01 PM GMT | Reuters

8 November 2022 04:01 p.m. ​All figures in US dollars. The loss announced by Adaptimmune Therapeutics PLC in the third quarter were on par with the Refinitiv mean estimate of losses. The company

Read More...
Adaptimmune Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

Adaptimmune Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

  • November 08, 2022 04:00 PM GMT | Reuters

* Adaptimmune Therapeutics PLC reported a quarterly adjusted loss of 24 cents​​ per share for the quarter ended in September. The mean expectation of seven analysts for the quarter was for a loss of

Read More...
Achilles Therapeutics PLC <ACHL.O>: Losses of 32  cents announced for third quarter

Achilles Therapeutics PLC <ACHL.O>: Losses of 32  cents announced for third quarter

  • November 08, 2022 01:31 PM GMT | Reuters

8 November 2022 01:30 p.m. ​All figures in US dollars. The loss announced by Achilles Therapeutics PLC in the third quarter were higher than the Refinitiv mean estimate of losses. The company reported

Read More...
Achilles Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

Achilles Therapeutics PLC reports results for the quarter ended in September - Earnings Summary

  • November 08, 2022 01:30 PM GMT | Reuters

* Achilles Therapeutics PLC reported a quarterly adjusted loss of 32 cents​​ per share for the quarter ended in September. The mean expectation of five analysts for the quarter was for a loss of 55

Read More...
CVS Group Sees 5 Year Ambition Of Organic Revenue Growth Between 4% - 8% Per Annum

CVS Group Sees 5 Year Ambition Of Organic Revenue Growth Between 4% - 8% Per Annum

  • November 08, 2022 07:25 AM GMT | Reuters

Nov 8 (Reuters) - CVS Group PLC: * CVS GROUP PLC: FIVE YEAR AMBITION OF ORGANIC REVENUE GROWTH OF BETWEEN 4% AND 8% PER ANNUM AND ADJUSTED EBITDA MARGIN BETWEEN 19% AND 23% * CVS GROUP PLC: GROUP'S

Read More...
Theravance Biopharma Inc <TBPH.O>: Profits of $12.14 announced for third quarter

Theravance Biopharma Inc <TBPH.O>: Profits of $12.14 announced for third quarter

  • November 08, 2022 01:54 AM GMT | Reuters

8 November 2022 01:54 a.m. ​All figures in US dollars. The profits announced by Theravance Biopharma Inc in the third quarter were higher than the Refinitiv mean estimate of losses. The company

Read More...